In human patients treated with rapamycin and its derivative mTOR inhibitor, everolimus, moderate hypertriglyceridemia and mild to moderate hypercholesterolemia are relatively common while severe hypertriglyceridemia is rare (42, 48–51). The gene discussed is MTOR; the disease is familial hypercholesterolemia.